Quantbot Technologies LP lessened its position in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) by 36.5% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,853 shares of the biopharmaceutical company’s stock after selling 1,640 shares during the period. Quantbot Technologies LP’s holdings in Esperion Therapeutics were worth $132,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of ESPR. FMR LLC raised its position in shares of Esperion Therapeutics by 2.3% in the second quarter. FMR LLC now owns 1,338,588 shares of the biopharmaceutical company’s stock valued at $61,950,000 after buying an additional 30,000 shares in the last quarter. Boxer Capital LLC acquired a new stake in shares of Esperion Therapeutics in the first quarter valued at approximately $45,020,000. Credit Suisse AG raised its position in shares of Esperion Therapeutics by 26.4% in the first quarter. Credit Suisse AG now owns 878,824 shares of the biopharmaceutical company’s stock valued at $31,030,000 after buying an additional 183,440 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Esperion Therapeutics by 4.4% in the second quarter. Vanguard Group Inc. now owns 756,224 shares of the biopharmaceutical company’s stock valued at $34,997,000 after buying an additional 32,074 shares in the last quarter. Finally, RA Capital Management LLC acquired a new stake in shares of Esperion Therapeutics in the first quarter valued at approximately $24,883,000. Institutional investors own 83.30% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another website, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The legal version of this piece can be read at https://www.thecerbatgem.com/2017/10/08/esperion-therapeutics-inc-espr-shares-sold-by-quantbot-technologies-lp.html.

Shares of Esperion Therapeutics, Inc. (NASDAQ ESPR) opened at 56.21 on Friday. The company’s market cap is $1.27 billion. The company has a 50 day moving average of $49.85 and a 200 day moving average of $42.60. Esperion Therapeutics, Inc. has a 52 week low of $9.40 and a 52 week high of $57.38.

Esperion Therapeutics (NASDAQ:ESPR) last issued its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.92) EPS for the quarter, missing analysts’ consensus estimates of ($1.67) by ($0.25). During the same period in the prior year, the firm posted ($0.62) EPS. On average, analysts expect that Esperion Therapeutics, Inc. will post ($7.29) EPS for the current year.

A number of research firms have recently weighed in on ESPR. Stifel Nicolaus reiterated a “buy” rating and issued a $70.00 price target on shares of Esperion Therapeutics in a research report on Wednesday. Northland Securities reiterated a “buy” rating and issued a $72.00 price target on shares of Esperion Therapeutics in a research report on Wednesday. Cowen and Company began coverage on shares of Esperion Therapeutics in a research report on Thursday, September 7th. They issued an “outperform” rating and a $64.00 price target for the company. Zacks Investment Research upgraded shares of Esperion Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, August 23rd. Finally, Jefferies Group LLC reiterated a “buy” rating and issued a $85.00 price target on shares of Esperion Therapeutics in a research report on Monday, August 21st. Seven equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $55.35.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.

Institutional Ownership by Quarter for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Stock Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related stocks with our FREE daily email newsletter.